{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T11:47:46Z","timestamp":1740138466227,"version":"3.37.3"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s12032-017-0982-6","type":"journal-article","created":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T06:25:23Z","timestamp":1496298323000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical significance of androgen secretion disorders in men with a malignancy"],"prefix":"10.1007","volume":"34","author":[{"given":"Pawel J.","family":"Wiechno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazyna M.","family":"Poniatowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wojciech","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5388-8910","authenticated-orcid":false,"given":"Jakub","family":"Kucharz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malgorzata","family":"Sadowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Jonska-Gmyrek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karol","family":"Nietupski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Rzymowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Demkow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,1]]},"reference":[{"key":"982_CR1","first-page":"440","volume":"8","author":"American Association of Clinical Endocrinologists","year":"2002","unstructured":"American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients: 2002 update. Endocr Pract. 2002;8:440\u201356.","journal-title":"Endocr Pract"},{"key":"982_CR2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.eururo.2008.08.033","volume":"55","author":"American Society of Andrology","year":"2009","unstructured":"American Society of Andrology. Investigation, treatment, and monitoring of late-onset hypogonadismin males: ISA, ISSAM, EAU, EAA, and ASA recommendations. Eur Urol. 2009;55:121\u201330.","journal-title":"Eur Urol"},{"key":"982_CR3","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.juro.2011.11.095","volume":"187","author":"BD Anawalt","year":"2012","unstructured":"Anawalt BD, Hotaling JM, Walsh TJ, Matsumoto AM. Performance of total testosterone measurement to predict free testosterone for the biochemical evaluation of male hypogonadism. J Urol. 2012;187:1369\u201373.","journal-title":"J Urol"},{"key":"982_CR4","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/er.2004-0013","volume":"26","author":"JM Kaufman","year":"2005","unstructured":"Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev. 2005;26:833\u201376.","journal-title":"Endocr Rev"},{"key":"982_CR5","doi-asserted-by":"crossref","first-page":"17718","DOI":"10.1073\/pnas.0608556103","volume":"103","author":"C Zhang","year":"2006","unstructured":"Zhang C, Yeh S. Chen YT I wsp: oligozoospermia with normal fertility in male mice lacking the androgen receptor in testis peritubular myoid cells. Proc Natl Acad Sci. 2006;103:17718\u201323.","journal-title":"Proc Natl Acad Sci"},{"key":"982_CR6","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1210\/en.2003-0741","volume":"144","author":"R Singh","year":"2003","unstructured":"Singh R, Artaza JN, Taylor WE, et al. Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1\/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology. 2003;144:5081.","journal-title":"Endocrinology"},{"key":"982_CR7","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1016\/S0140-6736(00)02249-2","volume":"355","author":"JL Spivak","year":"2000","unstructured":"Spivak JL. The blood in systemic disorders. Lancet. 2000;355:1707\u201312.","journal-title":"Lancet"},{"key":"982_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/tam.6.1.1.7","volume":"6","author":"MA Boyanov","year":"2003","unstructured":"Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6:1.","journal-title":"Aging Male"},{"key":"982_CR9","unstructured":"Szczeklik A et al. Evidence-based textbook of internal medicine\u2014Szczeklik\u2019s Internal Medicine 2012; p. 1360."},{"key":"982_CR10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.tics.2005.12.010","volume":"10","author":"JS Janowsky","year":"2006","unstructured":"Janowsky JS. Thinking with your gonads: testosterone and cognitive. Trends Cog Sci. 2006;10:77\u201382.","journal-title":"Trends Cog Sci"},{"key":"982_CR11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/(SICI)1097-4547(19970115)47:2<198::AID-JNR8>3.0.CO;2-A","volume":"47","author":"P Tirassa","year":"1997","unstructured":"Tirassa P, Thilbin I, Angren G, et al. High-dose anabolic androgenic steroids modulate concentrations of nerve growth factor and expression of its low affinity receptor in male rat brain. J Neurosci Res. 1997;47:198\u2013207.","journal-title":"J Neurosci Res"},{"key":"982_CR12","first-page":"417","volume":"5","author":"T Shanmugalingam","year":"2013","unstructured":"Shanmugalingam T, Soultati A, Chowdhury S, Rudman S, Van Hemelrijck M. Global incidence and outcome of testicular cancer. Clin Epidemiol. 2013;5:417\u201327.","journal-title":"Clin Epidemiol"},{"key":"982_CR13","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1111\/j.1365-2605.2010.01123.x","volume":"34","author":"G P\u00fchse","year":"2011","unstructured":"P\u00fchse G, Secker A, Kemper S, Hertle L, Kliesch S. Testosterone deficiency in testicular germ-cell cancer patients is not influenced by oncological treatment. Int J Androl. 2011;34:e351\u20137.","journal-title":"Int J Androl"},{"key":"982_CR14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/S0302-2838(03)00263-X","volume":"44","author":"C Nord","year":"2003","unstructured":"Nord C, Bj\u00f8ro T, Ellingsen D, et al. Gonadal hormones in long-term survivors 10\u00a0years after treatment for unilateral testicular cancer. Eur Urol. 2003;44:322\u20138.","journal-title":"Eur Urol"},{"key":"982_CR15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-07-0684","volume":"158","author":"J Eberhard","year":"2008","unstructured":"Eberhard J, St\u00e5hl O, Cwikiel M, Cavallin-St\u00e5hl E, Giwercman Y, Salmonson EC, Giwercman A. Risk factors for post-treatment hypogonadism in testicular cancer patients. Eur J Endocrinol. 2008;158:561\u201370.","journal-title":"Eur J Endocrinol"},{"key":"982_CR16","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/bjc.1996.213","volume":"73","author":"CC Berger","year":"1996","unstructured":"Berger CC, Bokemeyer C, Schuppert F, Schmoll HJ. Endocrinological late effects after chemotherapy for testicular cancer. Br J Cancer. 1996;73:1108\u201314.","journal-title":"Br J Cancer"},{"key":"982_CR17","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/1097-0142(20010401)91:7<1297::AID-CNCR1132>3.0.CO;2-Z","volume":"91","author":"A Gerl","year":"2001","unstructured":"Gerl A, Muhlbayer D, Hansmann G, Mraz W, Hiddemann W. The impact of chemotherapy on Leydig cell function in long term survivors of germ cell tumors. Cancer. 2001;91:1297\u2013303.","journal-title":"Cancer"},{"key":"982_CR18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.urology.2009.03.051","volume":"74","author":"JE Lackner","year":"2009","unstructured":"Lackner JE, Koller A, Schatzl G, Marberger M, Kratzik C. Androgen deficiency symptoms in testicular cancer survivors are associated with sexual problems but not with serum testosterone or therapy. Urology. 2009;74:825\u20139.","journal-title":"Urology"},{"key":"982_CR19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.4149\/neo_2009_06_473","volume":"56","author":"M Ondrusova","year":"2009","unstructured":"Ondrusova M, Ondrus D, Dusek L, Spanikova B. Damage of hormonal function and bone metabolism in long-term survivors of testicular cancer. Neoplasma. 2009;56:473\u20139.","journal-title":"Neoplasma"},{"key":"982_CR20","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.eururo.2007.05.012","volume":"52","author":"P Wiechno","year":"2007","unstructured":"Wiechno P, Demkow T, Kubiak K, Sadowska M, Kami\u0144ska J. The quality of life and hormonal disturbances in testicular cancer survivors in Cisplatin era. Eur Urol. 2007;52:1448\u201354.","journal-title":"Eur Urol"},{"key":"982_CR21","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/imj.12500","volume":"44","author":"B O\u2019Corrigan","year":"2014","unstructured":"O\u2019Corrigan B, Fournier M, Olver IN, Stockler MR, Whitford H, Toner GC, Thomson DB, Davis ID, Hanning F, Singhal N, Underhill C, Clingan P, McDonald A, Boland A, Grimison P. Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Testosterone deficiency and quality of life in Australasian testicular cancer survivors; a prospective cohort study. Intern Med J. 2014;44:813\u20137.","journal-title":"Intern Med J"},{"key":"982_CR22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/bjc.2013.226","volume":"109","author":"PM Willemse","year":"2013","unstructured":"Willemse PM, Burggraaf J, Hamdy NA, Weijl NI, Vossen CY, van Wulften L, van Steijn-van Tol AQ, Rosendaal FR, Osanto S. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer. 2013;109:60\u20137.","journal-title":"Br J Cancer"},{"key":"982_CR23","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.bjc.6602677","volume":"93","author":"RA Huddart","year":"2005","unstructured":"Huddart RA, Norman A, Moynihan C, Horwich A, Parker C, Nicholls E, Dearnaley DP. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer. 2005;93:200\u20137.","journal-title":"Br J Cancer"},{"key":"982_CR24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/mpo.2950120403","volume":"12","author":"DH Johnson","year":"1984","unstructured":"Johnson DH, Hainsworth JD, Linde RB, Greco FA. Testicular function following combination chemotherapy with cis-platin, vinblastine, and bleomycin. Med Pediatr Oncol. 1984;12:233\u20138.","journal-title":"Med Pediatr Oncol"},{"key":"982_CR25","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bjc.1990.106","volume":"61","author":"NS Stuart","year":"1990","unstructured":"Stuart NS, Woodroffe CM, Grundy R, Cullen MH. Longterm toxicity of chemotherapy for testicular cancer-the cost of cure. Br J Cancer. 1990;61:479\u201384.","journal-title":"Br J Cancer"},{"key":"982_CR26","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.ejca.2011.05.026","volume":"47","author":"M Bandak","year":"2011","unstructured":"Bandak M, Aksglaede L, Juul A, R\u00f8rth M, Daugaard G. The pituitary-Leydig cell axis before and after orchiectomy in patients with stage I testicular cancer. Eur J Cancer. 2011;47:2585\u201391.","journal-title":"Eur J Cancer"},{"key":"982_CR27","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/annonc\/mds527","volume":"24","author":"EC Haas de","year":"2013","unstructured":"de Haas EC, Altena R, Boezen HM, Zwart N, Smit AJ, Bakker SJ, van Roon AM, Postma A, Wolffenbuttel BH, Hoekstra HJ, van Leeuwen FE, Sleijfer DT, Gietema JA. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol. 2013;24:749\u201355.","journal-title":"Ann Oncol"},{"issue":"109","key":"982_CR28","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/bjc.2013.226","volume":"9","author":"PM Willemse","year":"2013","unstructured":"Willemse PM, Burggraaf J, Hamdy NA, Weijl NI, Vossen CY, van Wulften L, van Steijn-van Tol AQ, Rosendaal FR, Osanto S. Prevalence of the metabolic syndrome and cardiovascular disease risk in chemotherapy-treated testicular germ cell tumour survivors. Br J Cancer. 2013;9(109):60\u20137.","journal-title":"Br J Cancer"},{"key":"982_CR29","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2003.04.173","volume":"21","author":"RA Huddart","year":"2003","unstructured":"Huddart RA, Norman A, Shahidi M, Horwich A, Coward D, Nicholls J, Dearnaley DP. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol. 2003;21:1513\u201323.","journal-title":"J Clin Oncol"},{"key":"982_CR30","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jad.2009.06.035","volume":"122","author":"J Eberhard","year":"2010","unstructured":"Eberhard J, St\u00e5hl O, Cohn-Cedermark G, Cavallin-St\u00e5hl E, Giwercman Y, Rastkhani H, Rylander L, Eberhard-Gran M, Kvist U, Giwercman A. Emotional disorders in testicular cancer survivors in relation to hypogonadism, androgen receptor polymorphism and treatment modality. J Affect Disord. 2010;122:260\u20136.","journal-title":"J Affect Disord"},{"key":"982_CR31","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jacc.2009.04.078","volume":"54","author":"G Caminiti","year":"2009","unstructured":"Caminiti G, Volterrani M, Iellano F, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance and baroflex sensitivity in elderly patients with chronic heart failure: a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54:919\u201327.","journal-title":"J Am Coll Cardiol"},{"key":"982_CR32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1365-2265.2005.02339.x","volume":"63","author":"AM Isidori","year":"2005","unstructured":"Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, body metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol. 2005;63:280\u201393.","journal-title":"Clin Endocrinol"},{"key":"982_CR33","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1530\/eje.1.02166","volume":"154","author":"D Kapoor","year":"2006","unstructured":"Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899\u2013906.","journal-title":"Eur J Endocrinol"},{"key":"982_CR34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1530\/EJE-11-0221","volume":"165","author":"F Saad","year":"2011","unstructured":"Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocr. 2011;165:675\u201385.","journal-title":"Eur J Endocr"},{"key":"982_CR35","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1210\/jc.2006-0036","volume":"9","author":"MJ Tracz","year":"2006","unstructured":"Tracz MJ, Sideras K, Bolona ER, et al. Testosterone use in men and its effects on bone health. A systematic review and meta-analysis of randomized placebo-controlled trials. J Clin Endocrinol Metab. 2006;9:2011\u20136.","journal-title":"J Clin Endocrinol Metab"},{"key":"982_CR36","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1111\/j.1743-6109.2010.01765.x","volume":"7","author":"G Moon du","year":"2010","unstructured":"du Moon G, Park MG, Lee SW, et al. The efficacy and safety of testosterone undecanoate (Nebido\u00ae) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med. 2010;7:2253\u201360.","journal-title":"J Sex Med"},{"key":"982_CR37","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1111\/j.1743-6109.2010.01859.x","volume":"7","author":"EJ Giltay","year":"2010","unstructured":"Giltay EJ, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on depressive symptoms and sexual dysfunction in men with metabolic syndrome. J Sex Med. 2010;7:2572\u201382.","journal-title":"J Sex Med"},{"key":"982_CR38","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1055\/s-2001-16351","volume":"109","author":"M Zitzmann","year":"2001","unstructured":"Zitzmann M, Weckesser M, Schoner O, et al. Changes in cerebral glucose metabolism and visuospatial capability in hypogonadal males under testosterone substitution therapy. Exp Clin Endocrinol Diabetes. 2001;109:302\u20134.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"982_CR39","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","volume":"26","author":"C Parker","year":"2015","unstructured":"Parker C, Gillessen S, Heidenreich A, Horwich A. ESMO Guidelines Committe: cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v69\u201377.","journal-title":"Ann Oncol"},{"key":"982_CR40","unstructured":"Mottet N, Bellmunt J, Briers E, et al. Guidelines on prostate cancer. Eur Assoc Urol. 2015. Available online at: http:\/\/uroweb.org\/guideline\/prostate-cancer\/"},{"key":"982_CR41","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1200\/JCO.2006.05.9741","volume":"24","author":"M Braga-Basaria","year":"2006","unstructured":"Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979\u201383.","journal-title":"J Clin Oncol"},{"key":"982_CR42","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1569-9056(11)61074-9","volume":"10","author":"J Valverde","year":"2011","unstructured":"Valverde J, Planas Morin J, Salvador Lacambra C, et al. Prevalence of metabolic syndrome in prostate cancer patients under androgen-deprivation therapy: interim results of a case-control study. Eur Urol Suppl. 2011;10:337.","journal-title":"Eur Urol Suppl"},{"key":"982_CR43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","volume":"102","author":"NL Keating","year":"2010","unstructured":"Keating NL, O\u2019Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen-deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102:39\u201346.","journal-title":"J Natl Cancer Inst"},{"key":"982_CR44","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/aja.2011.83","volume":"13","author":"JJ Bo","year":"2011","unstructured":"Bo JJ, Zhang C, Zhang LH, et al. Androgen-deprivation therapy through bilateral orchiectomy: increased metabolic risks. Asian J Androl. 2011;13:833\u20137.","journal-title":"Asian J Androl"},{"key":"982_CR45","doi-asserted-by":"crossref","first-page":"E300","DOI":"10.5489\/cuaj.3655","volume":"10","author":"MM Rezaei","year":"2016","unstructured":"Rezaei MM, Rezaei MM, Ghoreifi A, Kerigh BF. Metabolic syndrome in patients with prostate cancer undergoing intermittent androgen-deprivation therapy. Can Urol Assoc J. 2016;10:E300\u20135.","journal-title":"Can Urol Assoc J"},{"key":"982_CR46","doi-asserted-by":"crossref","first-page":"e0117344","DOI":"10.1371\/journal.pone.0117344","volume":"10","author":"C Bosco","year":"2015","unstructured":"Bosco C, Crawley D, Adolfsson J, et al. Quantifying the evidence for the risk of metabolic syndrome and its components following androgen-deprivation therapy for prostate cancer: a meta-analysis. PLoS ONE. 2015;10:e0117344.","journal-title":"PLoS ONE"},{"key":"982_CR47","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2007.08.035","volume":"71","author":"MR Smith","year":"2008","unstructured":"Smith MR, Lee H, Fallon MA, Nathan DM. Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology. 2008;71:318.","journal-title":"Urology"},{"key":"982_CR48","doi-asserted-by":"crossref","first-page":"820403","DOI":"10.1155\/2015\/820403","volume":"2015","author":"MK Davis","year":"2015","unstructured":"Davis MK, Rajala JL, Tyldesley S, et al. The prevalence of cardiac risk factors in men with localized prostate cancer undergoing androgen-deprivation therapy in British Columbia, Canada. J Oncol. 2015;2015:820403.","journal-title":"J Oncol"},{"key":"982_CR49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1042\/cs1040195","volume":"104","author":"F Dockery","year":"2003","unstructured":"Dockery F, Bulpitt CJ, Agarwal S, Donaldson M, Rajkumar C. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci. 2003;104:195\u2013201.","journal-title":"Clin Sci"},{"key":"982_CR50","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1093\/jnci\/djm168","volume":"99","author":"HK Tsai","year":"2007","unstructured":"Tsai HK, D\u2019Amico AV, Sadetsky N, et al. Androgen-deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516\u201324.","journal-title":"J Natl Cancer Inst"},{"key":"982_CR51","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","volume":"27","author":"SM Alibhai","year":"2009","unstructured":"Alibhai SM, Duong-Hua M, Sutradhar R, et al. Impact of androgen-deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol. 2009;27:3452\u20138.","journal-title":"J Clin Oncol"},{"key":"982_CR52","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.eururo.2008.01.021","volume":"54","author":"JA Efstathiou","year":"2008","unstructured":"Efstathiou JA, Bae K, Shipley WU, et al. Cardiovascular mortality and duration of androgen-deprivation for locally advanced prostate cancer: analysis of RTOG 92\u201302. Eur Urol. 2008;54:816\u201323.","journal-title":"Eur Urol"},{"key":"982_CR53","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ijrobp.2010.03.018","volume":"80","author":"J Kim","year":"2011","unstructured":"Kim J, Vaid M, Tyldesley S, et al. Population-based study of cardiovascular mortality among patients with prostate cancer treated with radical external bean radiation therapy with and without adjuvant androgen-deprivation therapy at the British Columbia Cancer Agency. Int J Radiat Oncol Biol Phys. 2011;80:742\u201350.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"982_CR54","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1200\/JCO.2011.35.1494","volume":"29","author":"S Punnen","year":"2011","unstructured":"Punnen S, Cooperberg MR, Sadetsky N, et al. Androgen-deprivation therapy and cardiovascular risk. J Clin Oncol. 2011;29:3510\u20136.","journal-title":"J Clin Oncol"},{"key":"982_CR55","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.sxmr.2016.06.005","volume":"4","author":"TM Nguyen","year":"2016","unstructured":"Nguyen TM, Pastuszak AW. Testosterone therapy among prostate cancer survivors. Sex Med Rev. 2016;4:376\u201388.","journal-title":"Sex Med Rev"},{"key":"982_CR56","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565\u201373.","journal-title":"Eur Urol"},{"key":"982_CR57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00520-011-1271-0","volume":"20","author":"FT Baumann","year":"2012","unstructured":"Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in prostate cancer patients\u2014a systematic review of randomized controlled trials. Support Care Cancer. 2012;20:221\u201333.","journal-title":"Support Care Cancer"},{"key":"982_CR58","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1111\/j.1464-410X.2011.10555.x","volume":"109","author":"JP Nobes","year":"2011","unstructured":"Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy. BJU Int. 2011;109:1495\u2013502.","journal-title":"BJU Int"},{"key":"982_CR59","first-page":"465","volume":"166","author":"VB Shahinian","year":"2006","unstructured":"Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of the \u201candrogen deprivation syndrome\u201d in men receiving androgen deprivation for prostate cancer. Arch Intern Med. 2006;166:465\u201371.","journal-title":"Arch Intern Med"},{"key":"982_CR60","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","volume":"69","author":"J Morote","year":"2007","unstructured":"Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology. 2007;69:500\u20134.","journal-title":"Urology"},{"key":"982_CR61","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/pcan.2011.4","volume":"15","author":"A Serpa Neto","year":"2012","unstructured":"Serpa Neto A, Tobias-Machado M, Esteves MA, Senra MD, Wroclawski ML, Fonseca FL, Dos Reis RB, Pompeo AC. Giglio AD Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012;15:36\u201344.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"982_CR62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ejca.2015.09.011","volume":"53","author":"A Lipton","year":"2016","unstructured":"Lipton A, Fizazi K, Stopeck AT, Henry DH, Smith MR, Shore N, Martin M, Vadhan-Raj S, Brown JE, Richardson GE, Saad F, Yardley DA, Zhou K, Balakumaran A, Braun A. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics. Eur J Cancer. 2016;53:75\u201383.","journal-title":"Eur J Cancer"},{"key":"982_CR63","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1210\/jc.2014-4079","volume":"100","author":"BL Langdahl","year":"2015","unstructured":"Langdahl BL, Teglbj\u00e6rg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren \u00d6, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Mirza F, Siddhanti S, Orwoll E. A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial. J Clin Endocrinol Metab. 2015;100:1335\u201342.","journal-title":"J Clin Endocrinol Metab"},{"key":"982_CR64","first-page":"2547","volume":"12","author":"R Choo","year":"2005","unstructured":"Choo R, Chander S, Danjoux C, Morton G, Pearce A, et al. How are hemoglobin levels affected by androgen deprivation in non-metastatic prostate cancer patients. Can J Urol. 2005;12:2547\u201352.","journal-title":"Can J Urol"},{"key":"982_CR65","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1046\/j.1464-410X.1997.00234.x","volume":"79","author":"SB Strum","year":"1997","unstructured":"Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79:933\u201341.","journal-title":"Br J Urol"},{"key":"982_CR66","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.juro.2006.07.151","volume":"176","author":"F Joly","year":"2006","unstructured":"Joly F, Alibhai SM, Galica J, Park A, Yi QL, et al. Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer. J Urol. 2006;176:2443\u20137.","journal-title":"J Urol"},{"key":"982_CR67","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.maturitas.2009.10.017","volume":"65","author":"J Frisk","year":"2010","unstructured":"Frisk J. Managing hot flushes in men after prostate cancer\u2014a systematic review. Maturitas. 2010;65:15.","journal-title":"Maturitas"},{"key":"982_CR68","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294:238.","journal-title":"JAMA"},{"key":"982_CR69","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.juro.2015.03.026","volume":"194","author":"BD Gonzalez","year":"2015","unstructured":"Gonzalez BD, Jim HS, Donovan KA, Small BJ, Sutton SK, Park J, Lin HY, Spiess PE, Fishman MN, Jacobsen PB. Course and moderators of hot flash interference during androgen deprivation therapy for prostate cancer: a matched comparison. J Urol. 2015;194:690\u20135.","journal-title":"J Urol"},{"key":"982_CR70","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.critrevonc.2008.09.004","volume":"70","author":"SG Mohile","year":"2009","unstructured":"Mohile SG, Mustian K, Bylow K, Hall W, Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol. 2009;70:235\u201355.","journal-title":"Crit Rev Oncol Hematol"},{"key":"982_CR71","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","volume":"11","author":"J Irani","year":"2010","unstructured":"Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010;11:147\u201354.","journal-title":"Lancet Oncol"},{"key":"982_CR72","first-page":"128","volume":"8","author":"AR Moraska","year":"2010","unstructured":"Moraska AR, Atherton PJ, Szydlo DW, et al. Gabapentin for the management of hot flashes in prostate cancer survivors: a longitudinal continuation Study-NCCTG Trial N00CB. J Support Oncol. 2010;8:128\u201332.","journal-title":"J Support Oncol."},{"key":"982_CR73","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1188\/15.CJON.744-750","volume":"19","author":"L Feng","year":"2015","unstructured":"Feng L, Chen MK, Lukkahatai N, Hsiao CP, Kaushal A, Sechrest L, Saligan LN. Clinical predictors of fatigue in men with non-metastatic prostate cancer receiving external beam radiation therapy. Clin J Oncol Nurs. 2015;19:744\u201350.","journal-title":"Clin J Oncol Nurs."},{"key":"982_CR74","doi-asserted-by":"crossref","first-page":"4159","DOI":"10.1007\/s00520-016-3241-z","volume":"24","author":"AM Nelson","year":"2016","unstructured":"Nelson AM, Gonzalez BD, Jim HS, Cessna JM, Sutton SK, Small BJ, Fishman MN, Zachariah B. Jacobsen PB Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer. 2016;24:4159\u201366.","journal-title":"Support Care Cancer"},{"key":"982_CR75","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/pon.3909","volume":"25","author":"L Sharp","year":"2016","unstructured":"Sharp L, O\u2019Leary E, Kinnear H, Gavin A, Drummond FJ. Cancer-related symptoms predict psychological wellbeing among prostate cancer survivors: results from the PiCTure study. Psychooncology. 2016;25:282\u201391.","journal-title":"Psychooncology"},{"key":"982_CR76","doi-asserted-by":"crossref","first-page":"5030","DOI":"10.1200\/JCO.2010.30.8742","volume":"28","author":"SMH Alibhai","year":"2010","unstructured":"Alibhai SMH, Breunis H, Timilshina N, et al. Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol. 2010;28:5030\u201357.","journal-title":"J Clin Oncol"},{"key":"982_CR77","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/pon.2095","volume":"22","author":"PJ Wiechno","year":"2013","unstructured":"Wiechno PJ, Sadowska M, Kalinowski T, Michalski W, Demkow T. Does pharmacological castration as adjuvant therapy for prostate cancer after radiotherapy affect anxiety and depression levels, cognitive functions and quality of life? Psychooncology. 2013;22:346\u201351.","journal-title":"Psychooncology"},{"key":"982_CR78","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1007\/s00520-014-2285-1","volume":"22","author":"HL McGinty","year":"2014","unstructured":"McGinty HL, Phillips KM, Jim HS, et al. Cognitive functioning in men receiving androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Support Care Cancer. 2014;22:2271\u201380.","journal-title":"Support Care Cancer"},{"key":"982_CR79","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2015.64.1969","volume":"34","author":"KT Dinh","year":"2016","unstructured":"Dinh KT, Reznor G, Muralidhar V, Mahal BA, Nezolosky MD, Choueiri TK, Hoffman KE, Hu JC, Sweeney CJ, Trinh QD, Nguyen PL. Association of androgen deprivation therapy with depression in localized prostate cancer. J Clin Oncol. 2016;34:1905\u201312.","journal-title":"J Clin Oncol"},{"key":"982_CR80","first-page":"49","volume":"18","author":"T Kushnir","year":"2016","unstructured":"Kushnir T, Gofrit ON, Elkayam R, Paluch-Shimon S, Lawrence YR, Weiss L, Symon Z. Impact of Androgen deprivation therapy on sexual and hormonal function in patients receiving radiation therapy for prostate cancer. Isr Med Assoc J. 2016;18:49\u201353.","journal-title":"Isr Med Assoc J"},{"key":"982_CR81","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/j.juro.2012.01.080","volume":"187","author":"E Ng","year":"2012","unstructured":"Ng E, Woo HH, Turner S, Leong E, Jackson M, Spry N. The influence of testosterone suppression and recovery on sexual function in men with prostate cancer: observations from prospective study in men undergoing intermittent androgen suppression. J Urol. 2012;187:2162\u20136.","journal-title":"J Urol"},{"key":"982_CR82","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1111\/j.1743-6109.2010.01902.x","volume":"7","author":"S Elliott","year":"2010","unstructured":"Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW. ADT Survivorship Working Group Androgen deprivation therapy for prostate cancer: recommendations to improve patient and partner quality of life. J Sex Med. 2010;7:2996\u20133010.","journal-title":"J Sex Med"},{"key":"982_CR83","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/pcan.2014.10","volume":"17","author":"D Brungs","year":"2014","unstructured":"Brungs D, Chen J, Masson P, Epstein RJ. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostatecancer: results from a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2014;17:105\u201311.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"982_CR84","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","volume":"368","author":"M Hussain","year":"2013","unstructured":"Hussain M, Tangen CM, Higano CS, et al. Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): results of S9346 (INT-0162), an international phase III trial. N Engl J Med. 2013;368:1314\u201325.","journal-title":"N Engl J Med"},{"key":"982_CR85","unstructured":"International Agency for Research on Cancer, World Healt Organization: GLOBOCAN 2012: Estimated cancerIncidence, Mortality and Prevalence Worlswide in 2012. http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx ."},{"key":"982_CR86","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1002\/cncr.28619","volume":"120","author":"R Dev","year":"2014","unstructured":"Dev R, Hui D, Del Fabbro E, Delgado-Guay MO, Sobti N, Dalal S, Bruera E. Association between hypogonadism, symptom burden, and survival in male patients with advanced cancer. Cancer. 2014;120:1586\u201393.","journal-title":"Cancer"},{"key":"982_CR87","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1002\/cncr.20028","volume":"100","author":"A Rajagopal","year":"2004","unstructured":"Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, Kaur G, Bruera E. Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer. 2004;100:851\u20138.","journal-title":"Cancer"},{"key":"982_CR88","doi-asserted-by":"crossref","first-page":"E700","DOI":"10.1210\/jc.2011-2387","volume":"97","author":"BO Burney","year":"2012","unstructured":"Burney BO, Hayes TG, Smiechowska J, et al. Low testosterone levels and increased inflammatory markers in patients with cancer and relationship with cachexia. J Clin Endocrinol Metab. 2012;97:E700\u20139.","journal-title":"J Clin Endocrinol Metab"},{"key":"982_CR89","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1002\/cncr.21889","volume":"106","author":"JM Garcia","year":"2006","unstructured":"Garcia JM, Li H, Mann D, Epner D, Hayes TG, Marcelli M, et al. Hypogonadism in male patients with cancer. Cancer. 2006;106:2583\u201391.","journal-title":"Cancer"},{"key":"982_CR90","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00520-010-0832-y","volume":"19","author":"RJ Skipworth","year":"2011","unstructured":"Skipworth RJ, Moses AG, Sangster K, Sturgeon CM, Voss AC, Fallon MT, et al. Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer. 2011;19:391\u2013401.","journal-title":"Support Care Cancer"},{"key":"982_CR91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.brainres.2005.11.001","volume":"1070","author":"F Pimpinelli","year":"2006","unstructured":"Pimpinelli F, Parenti M, Guzzi F, Piva F, Hokfelt T, Maggi R. Presence of delta opioid receptors on a subset of hypothalamic gonadotropin releasing hormone (GnRH) neurons. Brain Res. 2006;1070:15\u201323.","journal-title":"Brain Res"},{"key":"982_CR92","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/clpt.1984.75","volume":"35","author":"JH Mendelson","year":"1984","unstructured":"Mendelson JH, Ellingboe J, Judson BA, Goldstein A. Plasma testosterone and luteinizing hormone levels during levo-alpha-acetylmethadol maintenance and withdrawal. Clin Pharmacol Ther. 1984;35:545\u20137.","journal-title":"Clin Pharmacol Ther"},{"key":"982_CR93","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1200\/JCO.1999.17.5.1493","volume":"17","author":"SJ Howell","year":"1999","unstructured":"Howell SJ, Radford JA, Ryder WD, Shalet SM. Testicular function after cytotoxic chemotherapy: evidence of Leydig cell insufficiency. J Clin Oncol. 1999;17:1493\u20138.","journal-title":"J Clin Oncol"},{"key":"982_CR94","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2310\/JIM.0b013e3181cf91ca","volume":"58","author":"J Smiechowska","year":"2010","unstructured":"Smiechowska J, Utech A, Taffet G, Hayes T, Marcelli M, Garcia JM. Adipokines in patients with cancer anorexia and cachexia. J Investig Med. 2010;58:554\u20139.","journal-title":"J Investig Med"},{"key":"982_CR95","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.1999.17.10.3299","volume":"17","author":"CL Loprinzi","year":"1999","unstructured":"Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia\/cachexia. J Clin Oncol. 1999;17:3299\u2013306.","journal-title":"J Clin Oncol"},{"issue":"9","key":"982_CR96","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1007\/s00520-013-1832-5","volume":"21","author":"E Fabbro Del","year":"2013","unstructured":"Del Fabbro E, Garcia JM, Dev R, et al. Testosterone replacement for fatigue in hypogonadal ambulatory males with advanced cancer: a preliminary double-blind placebo-controlled trial. Support Care Cancer. 2013;21(9):2599\u2013607.","journal-title":"Support Care Cancer"},{"key":"982_CR97","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1365-2265.2010.03845.x","volume":"73","author":"SY Kalinchenko","year":"2010","unstructured":"Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol. 2010;73:602\u201312.","journal-title":"Clin Endocrinol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-017-0982-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-0982-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-017-0982-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T04:45:10Z","timestamp":1602218710000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-017-0982-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,1]]},"references-count":97,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["982"],"URL":"https:\/\/doi.org\/10.1007\/s12032-017-0982-6","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"type":"print","value":"1357-0560"},{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2017,6,1]]},"article-number":"123"}}